CCO Oncology Podcast
169 episodes - English - Latest episode: about 1 month ago -Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Expert Insights on Optimal Current Management of Patients With Cholangiocarcinoma
March 21, 2022 18:00 - 34 minutes - 31.2 MBIn this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include: Initial diagnosis Biomarker testing to guide treatment with immunotherapies and targeted agents Adverse event management Strategies for counseling patients Presenters: Christine Chio, PharmD, BCOP Clinical Ambulatory GI Oncology Pharmacist Department of Pharmacy Massachusetts General Hospit...
Cancer Conversations: 3 Case Challenges of Real Patients With Myelodysplastic Syndromes
March 14, 2022 20:30 - 28 minutes - 25.8 MBIn this podcast episode, Amy DeZern, MD, MHS, Daniel Pollyea, MD, MS, and Amer Zeidan, MBBS, discuss challenging cases in MDS, including Treatment for MDS after ESA failure Strategies for patients with intermediate- or high-risk MDS Luspatercept therapy in MDS MDS case challenges Link to full program, including downloadable slidesets: https://bit.ly/3tYwcYu Presenters: Amy E. DeZern, MD, MHS Associate Professor Oncology and Medicine The Johns Hopkins University School of Medicine Balt...
Expert Insights on Targeted Therapies for Advanced Systemic Mastocytosis
March 10, 2022 21:35 - 39 minutes - 36.4 MBIn this episode, Dr Prithviraj Bose, Pharmacist Caitlin R. Rausch, and Nurse Practitioner Ilene A. Galinsky discuss incorporating KIT-targeted therapies into management of patients with advanced systemic mastocytosis. Topics include: Diagnosis and prognosis of advanced systemic mastocytosis Clinical trial data on efficacy of avapritinib and midostaurin Monitoring for and managing key toxicities with avapritinib, including cognitive dysfunction Presenters: Prithviraj Bose, MD Associate P...
Advances in B-Cell Lymphomas: Understanding Current Treatment Approaches
February 25, 2022 21:30 - 30 minutes - 28.5 MBIn this episode, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphoma Marginal zone lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma Posttransplant lymphoproliferative disorder Presenters: Julie M. Vose, MD, MBA Chief, Division of Oncology and Hematology Neumann M. and Mildred E. Harris Professor Department of Internal Medicine University of Nebras...
TKIs for Advanced HCC in the Second Line and Beyond
February 22, 2022 17:00 - 17 minutes - 15.9 MBIn this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss second line treatment of patients with advanced hepatocellular carcinoma. Topics include: Available agents for the management of advanced hepatocellular carcinoma in the second line The current role of tyrosine kinase inhibitors in second-line treatment of advanced hepatocellular carcinoma Ongoing clinical trials in the second-line setting Presenters: Jos...
New Directions With PARP Inhibitors in Pancreatic Cancer
February 21, 2022 18:35 - 18 minutes - 17.3 MBIn this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include: Current treatment landscape and testing in the United States vs the United Kingdom Testing for molecular subgroups beyond BRCAm Using PARP inhibitors in earlier stages of the disease Learning from other cancers, such as prostate, breast, and ovarian Presenters: Eileen M. O’Reilly, MD...
Evolving Therapy for Myeloma: Experts Discuss Patient Case Examples
February 18, 2022 22:40 - 43 minutes - 39.6 MBIn this episode,Brian G.M. Durie, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD, discuss treatment approaches for multiple myeloma using example patient cases. Smoldering myeloma Induction therapy for autologous stem cell transplant–eligible patients First-line approaches for autologous stem cell transplant–ineligible patients Treatment after first relapse Selecting therapy for heavily pretreated myeloma Presenters: Brian G.M....
Expert Insights on Advances in Immune Thrombocytopenia
February 07, 2022 21:10 - 23 minutes - 21.9 MBIn this episode, Keith R. McCrae, MD; Nichola Cooper, MD; and Rachael Grace, MD, MMSc,provide expert insights on immune thrombocytopenia management, along with addressing frequently asked questions from a live CCO symposium. Topics include: New and emerging therapeutic options Special patient populations, including children The management of immune thrombocytopenia COVID-19 vaccinations and immune thrombocytopenia Presenters: Keith R. McCrae, MD Professor of Molecular Medicine Departme...
Precision Medicine for aTTP: Expert Answers to Your Questions
February 01, 2022 20:05 - 19 minutes - 18.4 MBIn this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including: Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phase Data for caplacizumab in pediatric patients with aTTP Initiating rituximab after completion of plasma exchange International Society o...
Precision Medicine for T-Cell Lymphomas: Expert Answers to Your Questions
January 31, 2022 22:30 - 17 minutes - 15.8 MBIn this episode, Steven M. Horwitz, MD; Francine Foss, MD; and Barbara Pro, MD, answer questions from an audience of healthcare professionals on topics related to the management of patients with T-cell lymphomas including: Threshold of CD30 positivity useful to inform brentuximab vedotin use in patients with CTCL and PTCL Managing relapsed mycosis fungoides after allogeneic SCT Experience with ALK inhibition in ALCL with central nervous system metastases Managing refractory pruritus in C...
Multidisciplinary Overview of EGFR-Mutated NSCLC: An Expert Panel Discussion From Biomarker Testing to Managing Progressive Disease
January 26, 2022 17:00 - 28 minutes - 26 MBIn this podcast episode, Conor Ernst Steuer, MD, a medical oncologist; Frank Schneider, MD, a pathologist; and Elise Hitron, MSN, FNP-C, a phase I clinical trials nurse practitioner, engage in a multidisciplinary discussion of the latest management strategies for EGFR-mutated NSCLC. Topics include: Testing for targetable biomarkers Talking with patients about biomarker testing Frontline therapy for EGFR-positive NSCLC Resistance to front-line osimertinib Treatment of EGFR TKI–resistant ...
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management
January 14, 2022 22:00 - 12 minutes - 11.9 MBIn this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: Which patients should have pharmacokinetic-guided therapy? Toxicities with PEGylated extended half-life products Factor VIII and bone health Factor VIII peaks, thrombotic risk, and cardiovascular disease Choosing between extended half-life products and emicizumab for active patients Role of fitusiran in the treatment paradigm if approved Presenters: Miguel A. E...
Induction and Maintenance Therapy for Fit Patients With AML Without Targetable Mutations
January 10, 2022 18:00 - 14 minutes - 13.5 MBIn this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses therapeutic options for younger, fit patients with AML and no targetable mutations. Topics include: Induction chemotherapy and consolidation therapy Use of gemtuzumab ozogamicin Management of sinusoidal obstruction syndrome Nursing considerations for younger, fit patients with AML Presenter: Ashley Leak Bryant, PhD, RN, OCN, FAAN Associate Professor School of Nursing UNC Lineberger Comprehensive Cancer Center ...
Strategies for Secondary AML and Emerging Therapies for AML
January 10, 2022 18:00 - 15 minutes - 14.3 MBIn this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses management strategies for secondary AML and novel therapies currently in clinical trials for AML. Topics include: Liposomal cytarabine plus daunorubicin for secondary AML An overview of emerging immune-based strategies for AML Evidence on immune-based therapies, including agents targeting CD47, TIM3, and bispecific antibodies Presenter: Sarah M. Tinsley, PhD, APRN, AOCN Nurse Practitioner Courtesy Assistant Professor ...
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations
January 10, 2022 18:00 - 18 minutes - 16.7 MBIn this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include: Approved and emerging treatment options for FLT3-mutated AML Management of adverse events associated with FLT3 inhibitors Therapies for IDH1- and IDH2-mutated AML Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors Presenters: Sarah M. Tinsley, PhD, APRN, AOCN Nurse Practit...
An Overview of AML and Treatment Strategies for Patients Unfit for Intensive Therapy
January 10, 2022 17:55 - 13 minutes - 12.1 MBIn this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses acute myeloid leukemia and management approaches for patients unfit for intensive chemotherapy, with a focus on the nursing perspective. Topics include: An overview of AML Identifying patients unfit for intensive therapy Treatment options for unfit patients including venetoclax combinations Adverse event profiles of treatment options Nursing considerations for managing patients with AML unfit for intensive therap...
Managing Lower-Risk Myelodysplastic Syndrome: Nursing Implications
December 22, 2021 22:00 - 11 minutes - 10.8 MBIn this podcast episode, Ashley Leak Bryant, PhD, RN, OCN, FAAN, discusses management strategies for lower-risk myelodysplastic syndrome (MDS) with a focus on the nursing perspective. Topics include Risk scoring and treatment algorithms Current and ongoing clinical trials in the lower-risk MDS setting Adverse event profiles of current treatment options Nursing considerations for managing a patient with lower-risk MDS Presenters: Ashley Leak Bryant, PhD, RN, OCN, FAAN Associate Profess...
Managing Higher-Risk and Relapsed/Refractory Myelodysplastic Syndromes: Nursing Implications
December 22, 2021 22:00 - 13 minutes - 12.1 MBIn this podcast episode,Sarah Tinsley, PhD, APRN, AOCN, discusses management strategies for higher-risk and relapsed/refractory (R/R) myelodysplastic syndromes (MDS) with a focus on the nursing perspective. Topics include: Current and ongoing clinical trials in the higher-risk and R/R MDS setting Therapies surrounding transplant Nursing considerations for managing a patient with higher risk and/or R/R MDS Presenters: Sarah Tinsley, PhD, APRN, AOCN Nurse Practitioner Courtesy Assistant ...
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer
December 17, 2021 23:00 - 12 minutes - 11.8 MBIn this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including: Transitioning from second- to third-line therapy Factors in selecting among available therapies Key predictors of improved outcomes with regorafenib vs TAS-102 Presenters: Chiara Cremolini, MD, PhD Medical Oncologist Unit of Medical Oncology 2 Azienda Ospedaliero...
The Evolving Role of TKIs in First-line Treatment of Advanced HCC
December 14, 2021 16:30 - 13 minutes - 12.2 MBIn this podcast episode from Clinical Care Options (CCO), Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss first-line treatment of patients with advanced hepatocellular carcinoma. Topics include: Atezolizumab plus bevacizumab as the current standard of care Contraindications to atezolizumab plus bevacizumab The current role of tyrosine kinase inhibitors in first-line treatment of advanced hepatocellular carcinoma Ongoing clinical trials in the first-line setting ...
Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers
November 23, 2021 21:30 - 21 minutes - 19.4 MBIn this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including: Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable...
Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer
November 23, 2021 19:10 - 15 minutes - 14.4 MBIn this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including: Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens Second-line therapeutic options after disease progression on an immunotherapy-based regimen Immunotherapy in patients with advanced NSCLC and brain metastases Distinguishing betwee...
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
November 09, 2021 21:00 - 13 minutes - 12.4 MBIn this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include: Mechanisms of acquired resistance to TRK inhibitor therapy Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib Safety profiles of first- vs second-generation TRK i...
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma
November 02, 2021 21:20 - 18 minutes - 16.8 MBIn this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma. Presenters: Jean-Yves Blay, MD, PhD Professor of Medical Oncology Department of Medicine Centre Leon Berard Lyon, France Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Professor Sarcoma Unit Royal M...
PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape
October 26, 2021 20:30 - 19 minutes - 18.2 MBIn this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include: Importance of germline and somatic testing Adverse events associated with PARP inhibitors Maintenance therapy in pancreatic cancer Presenters: Philip Agop Philip, MD, PhD, FRCP Professor School of Medicine Wayne State University Leader, Gastroin...
Optimal Dosing Strategies With Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
October 21, 2021 20:00 - 15 minutes - 14.7 MBIn this episode, Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, discuss key data supporting contemporary dosing strategies with the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including: Individualizing therapy Clinical data and experience informing optimal dosing Key adverse events Presenters: Kanwal Raghav, MD, MBBS Associate Professor, Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas ...
First-Generation TRK Inhibitors: Clinical Evidence and Indications
October 15, 2021 20:15 - 14 minutes - 13 MBIn this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss key clinical data leading to FDA approvals and current indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors and ROS1-positive NSCLC. Topics include: Basket trials leading to FDA approvals of larotrectinib and entrectinib Current pan-tumor indications for first-generation TRK inhibitors in NTRK fusion–positive solid tumors as well as ROS1-positive NSCLC Sequencing treatment with TRK in...
PARP Inhibitors in Ovarian Cancer: Experts Discuss Patient Cases and the Current Paradigm
October 14, 2021 21:00 - 13 minutes - 12.7 MBIn this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include: Maintenance therapy in ovarian cancer SOLO1, PRIMA, PAOLO-1 clinical data Role of bevacizumab in treatment of ovarian cancer Presenters: Nicoletta Colombo, MD Professor of Obstetrics and Gynecology University of Milan-Bicocca European Ins...
Counseling Patients and Caregivers on Prophylaxis Therapy for Severe Hemophilia A
October 08, 2021 20:15 - 14 minutes - 13 MBIn this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include: Overcoming challenges to adherence Choice of standard vs extended half-life factor VIII vs emicizumab Safety and efficacy data with emicizumab Presenter: Guy A. Young, MD Professor of Pediatrics Director, Hemostasis and Thrombosis Center ...
Rationale for NTRK Testing in Patients With Cancer
October 08, 2021 20:00 - 17 minutes - 15.8 MBIn this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include: Differences between NTRK fusions vs gene mutations Frequency of NTRK fusions by age and tumor type When to test patients for NTRK fusions and interpreting reports Methods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochem...
Expert Answers to HCP Questions on Androgen Deprivation Therapy for Prostate Cancer
October 07, 2021 20:20 - 19 minutes - 17.8 MBIn this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including: How to select between GnRH agonists and antagonists for initial androgen deprivation therapy? How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and meta...
Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer
September 29, 2021 20:35 - 23 minutes - 21.4 MBIn this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including: Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines o...
Expert Insight on New Evidence Poised to Change the Treatment Landscape in Melanoma
September 28, 2021 20:00 - 36 minutes - 33.5 MBIn this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease. Link to full program: https://bit.ly/3ogPjMo Follow along with the downloadable slideset: https://bit.ly/2XYNIzt Presenters: Jeffrey S. Weber, MD, PhD Deputy Director Laura and Isaac Perlmutter Cancer Center NYU Langone Health Professor of Medicine NY...
Expert Insight on Practice Changing From IGCS 2021 Informing Treatment for Endometrial, Ovarian, and Cervical Cancer
September 21, 2021 20:30 - 24 minutes - 22.6 MBIn this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding: A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR status A subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received...
Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs
August 24, 2021 20:30 - 26 minutes - 24.6 MBIn this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include: Treatment after first relapsed Optimal use of CAR T-cell therapy When to use selinexor and belantamab mafodotin COVID-19 vaccinations for patients with myeloma Presenters: Paul G. Richardson, MD R. J. Corman Professor of Medicine Harvard...
Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer
August 19, 2021 20:20 - 41 minutes - 38 MBIn this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include: How the experts currently use CDK4/6 inhibitors in clinical practice Clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021 Strategies for counseling patients receiving CDK4/6 inhibitors Presenters: Joyce O’S...
Essential Biomarker Testing in GI Cancers
August 18, 2021 21:15 - 17 minutes - 15.7 MBIn this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including: Current testing approaches, including IHC and PD-L1 assays and next-generation sequencing Tumor agnostic testing: MSI, TMB, and NTRK fusion testing Colon cancer: RAS, BRAF, and HER2 Gastric cancer: PD-L1, HER2, and more Pancreatic cancer: BRCA Biliary cancers: FGFR and IDH1 Liquid biopsies When to test Presenter: John L. Mar...
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
August 05, 2021 20:30 - 8 minutes - 7.4 MBIn this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including: Clinical role of Ki-67 testing Core biopsies for identifying potential benefit with neoadjuvant endocrine therapy Combining CDK4/6 inhibition with tamoxifen Presenters: Javier Cortes, MD, PhD Head, Breast Canc...
The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer
July 30, 2021 20:30 - 21 minutes - 20.1 MBIn this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include: Updated safety and patient preference data from the ARAMIS and ODENZA trials Choice of apalutamide, darolutamide, and enzalutamide Counseling patients on adverse events Managing patients with asymptomatic nonmetastatic C...
Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
July 27, 2021 20:30 - 13 minutes - 12.1 MBIn this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include: Atrial fibrillation Cardiac toxicity Musculoskeletal AEs Managing risk of infections Presenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse Practitioner Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland CE/AAPA credit available by visiting the online pro...
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 2: Patient Strategies for Self-Management
July 27, 2021 20:25 - 17 minutes - 16.3 MBIn this podcast episode, Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this second of 2 podcast episodes on avoiding AEs include: Patient adherence to oral medications Lifestyle changes Monitoring, recording, and reporting of AEs The role of the nurse The role of the patient AE management Presenter: Sandra E. Kurtin, PhD, ANP-C, AOCN Director, Advanced Practice and Clinical Integration The Univer...
Strategies for Avoiding Adverse Reactions to BTK Inhibitor Therapy, Part 1: Drug–Drug and Drug–Food Interactions
July 27, 2021 20:20 - 15 minutes - 13.9 MBIn this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include: Pharmacokinetics Drug metabolism Drug–drug interactions Drug–food interactions The role of CYP enzymes Foods to avoid Medication review Presenter: Sandra E. Kurtin, PhD, ANP-C, AOCN Director, Advanced Practice and Clinical Integration The University of Arizona Cancer Center Assis...
BTK Inhibitors in CLL and Lymphomas: Overview and Current Indications
July 23, 2021 20:30 - 13 minutes - 12.6 MBIn this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include: Rationale for inhibiting BTK MOA of BTK inhibitors Approved BTK inhibitors Recent clinical trial findings Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Presenter: Beth Faiman, PhD, MSN, APRN-BC, AOCN Nurse Practitioner Cleveland Clinic Taussig Cancer Instit...
Adverse Events Associated with BTK Inhibitor Treatment
July 23, 2021 20:30 - 12 minutes - 11.5 MBIn this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include: BTK inhibitor selectivity BTK inhibitor adverse event profiles Ibrutinib intolerance Management of common adverse events Presenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse Practitioner Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland CE/AAPA credit available by...
Radiopharmaceuticals in the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 20, 2021 22:00 - 21 minutes - 19.5 MBIn this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include: Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223 Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trial Ongoing trials evaluating radionuclides in co...
Expert Answers to HCP Questions on CAR T-Cell Therapy
July 19, 2021 20:30 - 18 minutes - 16.5 MBIn this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including: At what time in the treatment journey should CAR T-cell therapy be considered? How to select among 3 approved products for relapsed/refractory large B-cell lymphoma? How is CAR T-cell therapy best used for multiple myeloma? What qualities of bridging therap...
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on BCMA-Targeted Therapies
July 19, 2021 20:30 - 15 minutes - 14.4 MBIn this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University of Texas MD Anderson Cancer Center. Presenter: Donna Catamero, ANP-BC, OCN, CCRC Associate Di...
How to Integrate Novel Treatment Classes for R/R Myeloma Into Clinical Practice: Information on Selinexor, Venetoclax, and Melphalan Flufenamide
July 16, 2021 21:00 - 12 minutes - 11.8 MBIn this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Director of Myeloma Translational Research at the Mount Sinai Health System. Presenter: Tiffany...
Treatment Options for Patients With Multiple Myeloma After First Relapse
July 14, 2021 20:30 - 13 minutes - 12.4 MBIn this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include: Strategies for monitoring for disease progression Disease, therapy, and patient considerations for treatment selection at first relapse Nursing implications and supportive care considerations for patients receiving therapy for relapsed disease Presenter: Charise Gleason, MSN, NP-BC, AOCNP Advanc...
Caring for Patients With Newly Diagnosed Multiple Myeloma
July 14, 2021 20:30 - 12 minutes - 11.3 MBIn this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include: IMWG criteria for diagnosing smoldering and active myeloma Risk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS staging Individualizing initial treatment for ASCT-ineligible myeloma Selecting optimal initial treatment ...